These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34185608)

  • 1. A Whole-Body Physiologically Based Pharmacokinetic Model for Alpha Particle Emitting Bismuth in Rats.
    Zaid NRR; Kletting P; Winter G; Beer AJ; Glatting G
    Cancer Biother Radiopharm; 2022 Feb; 37(1):41-46. PubMed ID: 34185608
    [No Abstract]   [Full Text] [Related]  

  • 2. A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice.
    Zaid NRR; Kletting P; Winter G; Prasad V; Beer AJ; Glatting G
    Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
    Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
    Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
    Akabani G; Kennel SJ; Zalutsky MR
    J Nucl Med; 2003 May; 44(5):792-805. PubMed ID: 12732682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
    Lee D; Li M; Bednarz B; Schultz MK
    Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-Body Disposition and Physiologically Based Pharmacokinetic Modeling of Adeno-Associated Viruses and the Transgene Product.
    Liu S; Chowdhury EA; Xu V; Jerez A; Mahmood L; Ly BQ; Le HK; Nguyen A; Rajwade A; Meno-Tetang G; Shah DK
    J Pharm Sci; 2024 Jan; 113(1):141-157. PubMed ID: 37805073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
    Khot A; Tibbitts J; Rock D; Shah DK
    AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
    Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically based pharmacokinetic modeling of (18)F-SiFAlin-Asp3-PEG1-TATE in AR42J tumor bearing mice.
    Maaß C; Rivas JR; Attarwala AA; Hardiansyah D; Niedermoser S; Litau S; Wängler C; Wängler B; Glatting G
    Nucl Med Biol; 2016 Apr; 43(4):243-6. PubMed ID: 27067044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.
    Nakamae H; Wilbur DS; Hamlin DK; Thakar MS; Santos EB; Fisher DR; Kenoyer AL; Pagel JM; Press OW; Storb R; Sandmaier BM
    Cancer Res; 2009 Mar; 69(6):2408-15. PubMed ID: 19244101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment and Confirmation of Species Difference in Nonlinear Pharmacokinetics of Atipamezole with Physiologically Based Pharmacokinetic Modeling.
    Li Z; Gao Y; Yang C; Xiang Y; Zhang W; Zhang T; Su R; Lu C; Zhuang X
    Drug Metab Dispos; 2020 Jan; 48(1):41-51. PubMed ID: 31699808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocytosis mechanism in physiologically-based pharmacokinetic modeling of nanoparticles.
    Deng L; Liu H; Ma Y; Miao Y; Fu X; Deng Q
    Toxicol Appl Pharmacol; 2019 Dec; 384():114765. PubMed ID: 31669777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution and Multicompartment Pharmacokinetic Analysis of a Targeted α Particle Therapy.
    Tichacek CJ; Tafreshi NK; Kil H; Engelman RW; Doligalski ML; Budzevich MM; Gage KL; McLaughlin ML; Wadas TJ; Silva A; Moros E; Morse DL
    Mol Pharm; 2020 Nov; 17(11):4180-4188. PubMed ID: 32960613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining tissue distribution of the oral antileishmanial agent miltefosine: a physiologically-based pharmacokinetic modeling approach.
    Ramisetty BS; Yang S; Dorlo TPC; Wang MZ
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0032824. PubMed ID: 38842325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of targeted alpha therapy with
    Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Królicki B; Jakuciński M; Pawlak D; Apostolidis C; Mirzadeh S; Rola R; Merlo A; Morgenstern A
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):614-622. PubMed ID: 30498897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted alpha particle immunotherapy for myeloid leukemia.
    Jurcic JG; Larson SM; Sgouros G; McDevitt MR; Finn RD; Divgi CR; Ballangrud AM; Hamacher KA; Ma D; Humm JL; Brechbiel MW; Molinet R; Scheinberg DA
    Blood; 2002 Aug; 100(4):1233-9. PubMed ID: 12149203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mathematical Modeling of
    Zaid NRR; Kletting P; Beer AJ; Stallons TAR; Torgue JJ; Glatting G
    Cancer Biother Radiopharm; 2023 Oct; 38(8):528-535. PubMed ID: 33481653
    [No Abstract]   [Full Text] [Related]  

  • 18. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
    Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
    Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein.
    Miederer M; Seidl C; Beyer GJ; Charlton DE; Vranjes-Duric S; Comor JJ; Huber R; Nikula T; Apostolidis C; Schuhmacher C; Becker KF; Senekowitsch-Schmidtke R
    Radiat Res; 2003 May; 159(5):612-20. PubMed ID: 12710872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.
    Scotcher D; Melillo N; Tadimalla S; Darwich AS; Ziemian S; Ogungbenro K; Schütz G; Sourbron S; Galetin A
    Mol Pharm; 2021 Aug; 18(8):2997-3009. PubMed ID: 34283621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.